Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Eli Lilly and Co LLY

Healthcare Biotechnology
Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant... see more

Opinion & Analysis (NYSE:LLY)

    Morning Market Outlook for June 11, 2024

    TheUpTrend June 11, 2024

    Eli Lilly Trades Up 15% on Positive Phase 3 Breast Cancer Trial Results

    Streetwise Reports June 17, 2020

    Possible 'best-in-class' alzheimer's drug candidate offers 'disruptive' potential

    The Life Sciences Report September 21, 2017

    The ProMIS of an Alzheimer's cure

    The Life Sciences Report May 4, 2017

    Diffusion Pharmaceuticals takes aim at brain cancer: CEO David Kalergis

    The Life Sciences Report April 1, 2016

    The next leg of the health care boom is under way

    Dr. David Eifrig June 15, 2015

    Pharma ETFs in Focus on String of Earnings Beat - ETF News And Commentary

    Benzinga.com  July 30, 2014